《Iran & China at Forefront of Trading Week, Critical Metals Rally & NVO Slides》
$NVO看跌
NVO股价承压,因市场认为其战略计划不够大胆或推进不够快,不过40美元处存在技术支撑。
现在来谈谈Novo,也就是此前的Novo Nordisk。该公司股价今早承压。市场似乎对Novo公布的下一阶段战略计划感到不满。
Now let's talk about Novo, formerly known as Novo Nordisk. The company's shares are under pressure this morning. The market appears to be dissatisfied with the plan revealed by Novo regarding its strategy for the next phase.
显然,他们的减肥药曾需求旺盛,至少在初期阶段是如此。但如今,竞争已经进入这一领域,并抢走了他们的部分市场份额。
It is clear that they saw a large demand for their weight loss drug, at least in its early stages. But now, competition has entered this field and captured part of their market share.